The Annual General Meeting of 2018 decided that the Nomination Committee would be appointed as follows: “The Chairman of the Board shall convene the three largest shareholders in the Company, who each shall elect representative to be a member of the Nomination Committee together with the Chairman of the Board. In the establishment of the Nomination Committee, the ownership ratios as of June 30, 2018 shall determine the largest shareholders in terms of voting rights. The representative of the largest shareholder in the Nomination Committee at that time shall be the Chairman of the Nomination committee. If any of the three largest shareholders waives their right to appoint a member of the Nomination Committee, the next largest shareholder shall be allowed to appoint a member of the Nomination Committee.
In accordance with the AGM’s decision, the Nomination Committee was formed and consists of, apart from the Chairman of Infant Bacterial Therapeutics AB’s Board of Directors, Peter Rothschild, by Per-Erik Andersson, representative of the company’s largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who via direct and indirect ownership is the company’s second largest shareholder, as well as Jannis Kitsakis, representative of the company’s third largest shareholder, The Fourth Swedish National Pension Fund. All members of the Nomination Committee, apart from Peter Rothschild, are independent in relation to the company and company management.
The Nomination Committee is reached via the Nomination Committee Chairman, Per-Erik Andersson, at firstname.lastname@example.org, or by telephone: +46 70-537 98 92.
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) (“IBT”) is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is developing drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC) in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT has an additional project in its portfolio, a second rare disease program, IBP-1016, for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics (IBT B) shares are listed on Nasdaq Stockholm.
For additional information, please contact
Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 8 410 145 55